Beyond Air (XAIR) Q1 FY27 earnings call

Beyond Air is positioning for its next growth phase, strengthening its financial foundation and expanding commercial reach ahead of the anticipated FDA approval and launch of its second-generation LungFit PH system. While Q1 FY27 revenue remained flat, the company reported improved gross margins and significant progress in market access and pipeline development, reaffirming its full-year revenue guidance.